BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 26961346)

  • 21. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
    Greco FA; Hainsworth JD
    Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma.
    Freifeld Y; Ananthakrishnan L; Margulis V
    Curr Urol Rep; 2018 Aug; 19(10):82. PubMed ID: 30116909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inherited forms of renal cell carcinoma.
    Kiuru M; Kujala M; Aittomäki K
    Scand J Surg; 2004; 93(2):103-11. PubMed ID: 15285561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in renal cell carcinoma.
    D'Avella C; Abbosh P; Pal SK; Geynisman DM
    Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VHL and HIF signalling in renal cell carcinogenesis.
    Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
    J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic regulation in RCC: opportunities for therapeutic intervention?
    Larkin J; Goh XY; Vetter M; Pickering L; Swanton C
    Nat Rev Urol; 2012 Jan; 9(3):147-55. PubMed ID: 22249190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.
    Chen Y; Sun Y; Rao Q; Xu H; Li L; Chang C
    Oncotarget; 2015 Oct; 6(31):31203-15. PubMed ID: 26304926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and clinical value of SALL4 in renal cell carcinomas.
    Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
    Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular biology of renal cell carcinoma.
    Keefe SM; Nathanson KL; Rathmell WK
    Semin Oncol; 2013 Aug; 40(4):421-8. PubMed ID: 23972705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
    Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
    Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
    Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment and characterization of a renal cell carcinoma line from a patient with von Hippel-Lindau syndrome.
    Morash BA; Lee CL; Rowden G; Riddell DC; Guernsey DL
    Cancer Genet Cytogenet; 1997 Jul; 96(1):50-7. PubMed ID: 9209471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic kidney cancer syndromes.
    Ho TH; Jonasch E
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1347-55. PubMed ID: 25190700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma.
    Parker AS; Cheville JC; Lohse CM; Igel T; Leibovich BC; Blute ML
    Urology; 2005 Jun; 65(6):1090-5. PubMed ID: 15893810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.
    Nogueira I; Dias F; Teixeira AL; Medeiros R
    Pharmacogenomics; 2018 Feb; 19(3):249-261. PubMed ID: 29334302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [50 years of renal cell carcinoma].
    Doehn C
    Aktuelle Urol; 2019 Aug; 50(4):378-385. PubMed ID: 31398756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular genetics of renal cell carcinoma.
    Erlandsson R
    Cancer Genet Cytogenet; 1998 Jul; 104(1):1-18. PubMed ID: 9648552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.